Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL
February 10 2020 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage
biopharmaceutical company discovering and developing novel products
to treat cancer, with an initial focus on myelodysplastic syndromes
(MDS), today announced that Dr. Steven M. Fruchtman,
President and Chief Executive Officer, will present a company
update at NobleCon16 - Noble Capital Markets’ Sixteenth Annual
Investor Conference, February 17-18, 2020, being held in Hollywood,
FL. Dr. Fruchtman and members of management will be available
for 1x1 meetings during the conference.
Presentation details |
Date/Time: |
Monday, February 17th, 10:30 AM |
Venue: |
Seminole Hard Rock Hotel & Casino, Hollywood, FL |
|
Terrace Ballroom D |
Presenter: |
Steven Fruchtman, CEO |
A video webcast of the presentation will be
available the following day on the Company’s website at
https://investor.onconova.com/events-and-presentations, and as part
of a complete catalog of presentations available on Noble Capital
Markets’ Conference website: www.nobleconference.com and on
Channelchek: www.channelchek.com, the investor portal created by
Noble. The webcast will be archived on the company’s website,
the NobleCon website, and on Channelchek.com for 90 days following
the event.
About Onconova Therapeutics,
Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage
biopharmaceutical company focused on discovering and developing
novel small molecule drug candidates to treat cancer, with an
initial focus on Myelodysplastic Syndromes (MDS). Using a
proprietary chemistry platform, Onconova has created a pipeline of
targeted agents designed to work against specific cellular pathways
that are important in cancer cells. Advanced clinical trials
with the Company’s lead compound, rigosertib, are aimed at what the
Company believes are unmet medical needs of patients with
MDS. Onconova has conducted trials with two other research
compounds and has a pre-clinical program with a CDK4/6 and Ark5
inhibitor, ON 123300.
For more information, please visit
http://www.onconova.com.
About Noble Capital Markets,
Inc.
Noble Capital Markets (“Noble”) is a research
driven boutique investment bank that has supported small &
microcap companies since 1984. As a FINRA and SEC licensed
broker dealer Noble provides institutional-quality equity research,
merchant and investment banking, wealth management and order
execution services. In 2005, Noble established NobleCon, an
investor conference that has grown substantially over the last
decade. In 2018 Noble launched www.channelchek.com – a new
investment community dedicated exclusively to small and micro-cap
companies and their industries. Channelchek is tailored to
meet the needs of self-directed investors and financial
professionals. Channelchek is the first service to offer
institutional-quality research to the public, for FREE at every
level without a subscription. More than 6,000 emerging growth
companies are listed on the site, with growing content including
webcasts, podcasts, and balanced news.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova expectations regarding the
INSPIRE Trial and Onconova’s other development plans. Onconova has
attempted to identify forward-looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes. Although Onconova believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including Onconova's ability to continue as a going
concern, maintain its Nasdaq listing, the need for additional
financing, the success and timing of Onconova's clinical trials and
regulatory approval of protocols, our collaborations including the
effective termination of the HanX license and securities purchase
agreements and plans for partnering certain territories, and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this
release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated
events.
General Contact:
Avi Oler Onconova Therapeutics, Inc.
267-759-3680 ir@onconova.ushttp://www.onconova.com/contact/
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024